Kodiak Sciences (KOD) Projected to Post Earnings on Thursday

Kodiak Sciences (NASDAQ:KOD) will likely be issuing its Q3 2025 results before the market opens on Thursday, November 13th. Analysts expect the company to announce earnings of ($1.06) per share for the quarter. Individuals can find conference call details on the company’s upcoming Q3 2025 earningreport page for the latest details on the call scheduled for Thursday, November 13, 2025 at 4:00 PM ET.

Kodiak Sciences (NASDAQ:KOD) last posted its quarterly earnings results on Wednesday, August 13th. The company reported ($1.03) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.01) by ($0.02). On average, analysts expect Kodiak Sciences to post $-3 EPS for the current fiscal year and $-4 EPS for the next fiscal year.

Kodiak Sciences Trading Down 1.5%

KOD stock opened at $17.83 on Thursday. The firm has a 50 day moving average of $13.79 and a 200-day moving average of $8.27. Kodiak Sciences has a 12-month low of $1.92 and a 12-month high of $21.17. The company has a market cap of $941.78 million, a price-to-earnings ratio of -4.69 and a beta of 2.88.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of the business. Headlands Technologies LLC increased its stake in shares of Kodiak Sciences by 256.4% during the 2nd quarter. Headlands Technologies LLC now owns 8,083 shares of the company’s stock worth $30,000 after purchasing an additional 5,815 shares in the last quarter. Bridgeway Capital Management LLC boosted its position in Kodiak Sciences by 8.2% during the second quarter. Bridgeway Capital Management LLC now owns 101,900 shares of the company’s stock worth $380,000 after acquiring an additional 7,700 shares during the last quarter. Adage Capital Partners GP L.L.C. boosted its position in Kodiak Sciences by 55.1% during the second quarter. Adage Capital Partners GP L.L.C. now owns 2,055,707 shares of the company’s stock worth $7,668,000 after acquiring an additional 730,000 shares during the last quarter. Ameriprise Financial Inc. boosted its position in Kodiak Sciences by 171.3% during the second quarter. Ameriprise Financial Inc. now owns 266,354 shares of the company’s stock worth $994,000 after acquiring an additional 168,192 shares during the last quarter. Finally, Nantahala Capital Management LLC boosted its position in Kodiak Sciences by 11.3% during the second quarter. Nantahala Capital Management LLC now owns 590,884 shares of the company’s stock worth $2,204,000 after acquiring an additional 60,171 shares during the last quarter. 89.06% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently issued reports on the stock. HC Wainwright lifted their price target on shares of Kodiak Sciences from $3.00 to $5.00 and gave the company a “neutral” rating in a research report on Monday, August 18th. Chardan Capital reiterated a “neutral” rating and set a $14.00 price target on shares of Kodiak Sciences in a research report on Monday, October 6th. JPMorgan Chase & Co. upgraded shares of Kodiak Sciences from a “neutral” rating to an “overweight” rating and lifted their price target for the company from $15.00 to $24.00 in a research report on Friday, October 24th. Wall Street Zen downgraded shares of Kodiak Sciences from a “hold” rating to a “sell” rating in a research report on Saturday, October 11th. Finally, Jefferies Financial Group started coverage on shares of Kodiak Sciences in a research report on Monday, September 22nd. They set a “buy” rating and a $15.00 price target for the company. Three analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Hold” and an average target price of $19.17.

About Kodiak Sciences

Kodiak Sciences Inc, a clinical stage biopharmaceutical company, researches, develops, and commercializes therapeutics to treat retinal diseases. Its lead product candidate is tarcocimab tedromer (KSI-301), an anti-vascular endothelial growth factor antibody biopolymer that is in Phase IIb/III clinical study to treat wet age-related macular degeneration (AMD), as well as Phase III clinical study for the treatment of diabetic macular edema, naïve macular edema due to retinal vein occlusion, and non-proliferative diabetic retinopathy.